Comparison of the effects of hypolipidemic treatment on monocyte proinflammatory cytokine release in @entity1 and @entity1 with @entity164 2 XXXX and atherogenic dyslipidemia.

@entity1 @entity650 @entity3724 @entity32 @entity3413 @entity6 @entity1356 @entity5 @entity310 @entity6334 @entity2842 @entity164 @entity731 @entity3691
INTRODUCTION: Statins and fibrates reduce monocyte release of proinflammatory cytokines, but it remains unknown whether this effect is sex dependent. MATERIAL AND METHODS: We retrospectively analysed age-, weight-, and lipid-matched populations of @entity164 2 @entity6 @entity1 of both sexes, who, because of @entity731 , were treated with @entity3413 (40 mg daily), @entity3724 (200 mg daily), or @entity3413 plus @entity3724 . Monocyte release of @entity5 necrosis factor alpha ( @entity310 ), inteleukin-1beta, @entity650 , and @entity2842 ( @entity2842 ), as well as circulating levels of high-sensitivity C-reactive protein (hsCRP) and @entity3691 ( @entity6334 ) were assessed separately for @entity1 and @entity1 before and after 12 weeks of treatment. RESULTS: Baseline monocyte release of @entity310 , @entity1356 , @entity650 , and @entity2842 , as well as plasma hsCRP and @entity6334 levels were comparable in both sexes. @entity3413 , @entity3724 , and @entity3413 / @entity3724 combination therapy reduced monocyte release of @entity310 , inteleukin-1beta, @entity650 , and @entity2842 , with no difference between the treatment groups. The impact of @entity3413 and @entity3724 administered alone on monocyte cytokine release and systemic @entity32 did not differ between the @entity1 and @entity1 . The effect of @entity3413 / @entity3724 combination therapy on monocyte release of @entity650 and @entity2842 was more pronounced in the male population. The impact of @entity3413 administered together with @entity3724 on @entity310 , @entity1356 , and hsCRP was also stronger in the @entity1 than in the @entity1 , but the difference did not reach the level of significance. CONCLUSIONS: The obtained results suggest that sex differences determine the strength of the monocyte-suppressing effect of @entity3413 / / @entity3724 combination therapy in @entity164 2 @entity6 @entity1 with @entity731 . (Endokrynol Pol 2015; 66 (3): 224-230).
